A is the answer and the winners are Eze and Clement.
Details Below:
Disodium pamidronate is a biphosphonate that may be used in the prophyl-
axis and treatment of osteoporosis and corticosteroid-induced osteoporosis.
AV is receiving prednisolone as a long-term medication to suppress symptoms
of the disease. Discontinuation of treatment may lead to flare-ups of the
condition. Long-term use of corticosteroids is associated with onset of osteo-
porosis, diabetes and hypertension. AV is a post-menopausal woman who is
at a higher risk of developing osteoporosis, compared with the normal female
cohort group, as she is also receiving prednisolone long-term therapy. In AV
disodium pamidronate is used to counteract corticosteroid-induced osteo-
porosis. A disadvantage of disodium pamidronate is that it is only available
for slow intravenous infusion, which is given every 3 months, requiring the
patient to be hospitalised for about 3 h. Its use may lead to hypocalcaemia
and serum electrolytes should be monitored. Other biphosphonates such as
alendronic acid and risedronate, which are available as once weekly oral
formulations, may be considered as an alternative. AV is receiving calcium
and vitamin D supplementation to prevent hypocalcaemia and as bone
supplements in the management of osteoporosis.
A is the answer and the winners are Eze and Clement.
Details Below:
Disodium pamidronate is a biphosphonate that may be used in the prophyl-
axis and treatment of osteoporosis and corticosteroid-induced osteoporosis.
AV is receiving prednisolone as a long-term medication to suppress symptoms
of the disease. Discontinuation of treatment may lead to flare-ups of the
condition. Long-term use of corticosteroids is associated with onset of osteo-
porosis, diabetes and hypertension. AV is a post-menopausal woman who is
at a higher risk of developing osteoporosis, compared with the normal female
cohort group, as she is also receiving prednisolone long-term therapy. In AV
disodium pamidronate is used to counteract corticosteroid-induced osteo-
porosis. A disadvantage of disodium pamidronate is that it is only available
for slow intravenous infusion, which is given every 3 months, requiring the
patient to be hospitalised for about 3 h. Its use may lead to hypocalcaemia
and serum electrolytes should be monitored. Other biphosphonates such as
alendronic acid and risedronate, which are available as once weekly oral
formulations, may be considered as an alternative. AV is receiving calcium
and vitamin D supplementation to prevent hypocalcaemia and as bone
supplements in the management of osteoporosis.
A
A
A